JP2018520147A5 - - Google Patents

Download PDF

Info

Publication number
JP2018520147A5
JP2018520147A5 JP2017567249A JP2017567249A JP2018520147A5 JP 2018520147 A5 JP2018520147 A5 JP 2018520147A5 JP 2017567249 A JP2017567249 A JP 2017567249A JP 2017567249 A JP2017567249 A JP 2017567249A JP 2018520147 A5 JP2018520147 A5 JP 2018520147A5
Authority
JP
Japan
Prior art keywords
formula
diacid
crystal
pharmaceutical composition
ratio
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017567249A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018520147A (ja
JP6929234B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/039572 external-priority patent/WO2016210418A1/en
Publication of JP2018520147A publication Critical patent/JP2018520147A/ja
Publication of JP2018520147A5 publication Critical patent/JP2018520147A5/ja
Application granted granted Critical
Publication of JP6929234B2 publication Critical patent/JP6929234B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017567249A 2015-06-25 2016-06-27 医薬共結晶組成物及びその用途 Expired - Fee Related JP6929234B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562184591P 2015-06-25 2015-06-25
US62/184,591 2015-06-25
PCT/US2016/039572 WO2016210418A1 (en) 2015-06-25 2016-06-27 Pharmaceutical co-crystal composition and use thereof

Publications (3)

Publication Number Publication Date
JP2018520147A JP2018520147A (ja) 2018-07-26
JP2018520147A5 true JP2018520147A5 (enExample) 2019-07-18
JP6929234B2 JP6929234B2 (ja) 2021-09-01

Family

ID=57586692

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017567249A Expired - Fee Related JP6929234B2 (ja) 2015-06-25 2016-06-27 医薬共結晶組成物及びその用途

Country Status (8)

Country Link
US (3) US10428099B2 (enExample)
EP (1) EP3297640A4 (enExample)
JP (1) JP6929234B2 (enExample)
KR (1) KR20180021805A (enExample)
CN (2) CN116854745A (enExample)
AU (1) AU2016284816B2 (enExample)
CA (1) CA2989001A1 (enExample)
WO (1) WO2016210418A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016187191A1 (en) 2015-05-18 2016-11-24 Medoc Pharmaceutical Co., Ltd. A pharmaceutical co-crystal and use thereof
CA2988989A1 (en) 2015-06-19 2016-12-22 Syn-Nat Products Enterprise LLC Composition containing carboplatin and use
WO2016205785A1 (en) 2015-06-19 2016-12-22 Syn-Nat Products Enterprise LLC Pharmaceutical composition of carboplatin based co-crystals and use thereof
JP6929234B2 (ja) 2015-06-25 2021-09-01 シン−ナット プロダクツ エンタープライズ エルエルシー 医薬共結晶組成物及びその用途
CN111356454B (zh) * 2017-11-21 2023-04-07 湖南湘源美东医药科技有限公司 含有双环铂的组合产品、其制备方法及其用途
EP3845544B1 (en) 2018-09-01 2023-11-15 Beijing Showby Pharmaceutical Co., Ltd. Phosphate of platinum compound and preparation method therefor
CN111205332B (zh) * 2020-02-25 2025-03-21 华东理工大学 奥沙利铂-黄酮药物共晶及其制备方法和应用
WO2023093837A1 (zh) * 2021-11-26 2023-06-01 湖南湘源美东医药科技有限公司 含有铂类药物或者铂类药物共晶的药物组合物及其用途
CN116891436A (zh) * 2023-04-11 2023-10-17 齐泽(云南)生物科技有限公司 一种药用化合物的制备方法
CN116217628B (zh) * 2023-05-08 2023-07-14 华东理工常熟研究院有限公司 奥沙利铂Pt(IV)配合物的共晶及其制备方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5922689A (en) 1995-09-11 1999-07-13 Unitech Pharmaceuticals, Inc. Cisplatin analogs for cancer treatment
US6297245B1 (en) 1998-08-04 2001-10-02 Unitech Pharmaceuticals Cisplatin and folic acid administered to treat breast cancer
KR100317473B1 (ko) * 1999-05-11 2001-12-22 이계호 신규의 백금(iv)착제 및 그 제조방법
CN1121380C (zh) * 2000-03-03 2003-09-17 北京兴大豪斯科技有限公司 一种抗肿瘤的双二羧酸二氨络铂衍生物及其药物组合物
AUPQ641100A0 (en) 2000-03-23 2000-04-15 Australia Nuclear Science & Technology Organisation Methods of synthesis and use of radiolabelled platinum chemotherapeutic ag ents
AU2002221514A1 (en) * 2001-11-30 2003-06-10 Huisheng Qu Supermolecular carboplatinum derivatives, their preparation and pharmaceutical composition containing them as active ingredient and applications of the compositions
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
ATE502635T1 (de) 2002-08-19 2011-04-15 Pfizer Kombinationstherapie gegen hyperproliferative erkrankungen
CA2514092C (en) * 2003-01-21 2013-03-19 S.S.C.I., Inc. Novel cocrystallization of hydrochloric acid salt of an active agent
JP2007524596A (ja) * 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
WO2004099224A1 (de) 2003-05-05 2004-11-18 Universität Regensburg Carboplatin-artige platin (ii)- komplexe
WO2005023824A2 (en) 2003-08-13 2005-03-17 University Of South Florida Methods for inhibiting tumor cell proliferation
CN101972240B (zh) * 2003-09-04 2012-07-25 赛福伦公司 莫达芬尼组合物
EP1727520A2 (en) * 2003-12-09 2006-12-06 Medcrystalforms, Llc Method of preparation of mixed phase co-crystals with active agents
WO2006077424A1 (en) 2005-01-21 2006-07-27 Astex Therapeutics Limited Pharmaceutical compounds
ZA200806748B (en) 2006-01-30 2010-01-27 Platco Technologies Proprietar Preparation of platinum (II) complexes
ES2556677T3 (es) 2006-08-02 2016-01-19 Sunesis Pharmaceuticals, Inc. Utilización combinada de ácido (+)-1,4-dihidro-7-[(3S,4S)-3-metoxi-4-(metilamino)-1-pirrolidinil]-4-oxo-1-(2-tiazolil)-1,8-naftiridin-3-carboxílico y citarabina (Ara-C) para el tratamiento de la leucemia
WO2010029577A2 (en) 2008-09-15 2010-03-18 Ganga Raju Gokaraju Anti-cancer drugs and uses relating thereto for metastatic malignant melanoma and other cancers
CZ302618B6 (cs) 2009-09-10 2011-08-03 Univerzita Palackého Cyklobutan-1,1-dikarboxylátokomplexy platiny s deriváty N6-benzyladeninu, zpusoby jejich prípravy a použití techto komplexu jako léciv v protinádorové terapii
CN102791294A (zh) * 2009-12-16 2012-11-21 布里格姆妇女医院股份有限公司 用于多种药物递送的粒子
US20110287110A1 (en) 2010-04-23 2011-11-24 Mark Wesley Dewhirst Combination cancer treatment
CN102863474A (zh) * 2011-07-09 2013-01-09 陈小平 一类治疗细胞增殖性疾病的铂化合物、其制备方法和应用
JP5179628B2 (ja) 2011-07-15 2013-04-10 ユニーテック株式会社 4価白金錯体及びそれを含む医薬組成物
CN102993239A (zh) * 2011-09-19 2013-03-27 陈小平 离去基团含氨基或烷胺基的丁二酸衍生物的铂类化合物
US9220705B2 (en) 2013-03-07 2015-12-29 James David Hoeschele Method of treating colorectal cancer
HUE041877T2 (hu) 2013-10-17 2019-06-28 Vertex Pharma (S)-N-Metil-8-(1-((2'-metil-[4,5'-bipirimidin]-6-il)amino)propán-2-il)kinolin-4-karboxamid kokristályai és deuterált származékai DNS-PK inhibitorokként
CN104127402B (zh) 2014-08-15 2019-08-30 北京默加农生物技术发展有限公司 双环铂在制备抗病毒药物和抗菌药物中的应用
RU2676269C1 (ru) 2015-04-10 2018-12-27 Син-Нат Продактс Энтерпрайз Ллс Способ получения дициклоплатина
EP3285758B1 (en) 2015-04-22 2020-04-08 Syn-Nat Products Enterprise LLC Co-crystal composition and its pharmaceutical use
WO2016187191A1 (en) * 2015-05-18 2016-11-24 Medoc Pharmaceutical Co., Ltd. A pharmaceutical co-crystal and use thereof
CA2988989A1 (en) 2015-06-19 2016-12-22 Syn-Nat Products Enterprise LLC Composition containing carboplatin and use
WO2016205785A1 (en) 2015-06-19 2016-12-22 Syn-Nat Products Enterprise LLC Pharmaceutical composition of carboplatin based co-crystals and use thereof
JP6929234B2 (ja) 2015-06-25 2021-09-01 シン−ナット プロダクツ エンタープライズ エルエルシー 医薬共結晶組成物及びその用途

Similar Documents

Publication Publication Date Title
JP2018520147A5 (enExample)
JP6606692B2 (ja) (2R,5S,13AR)−8−ヒドロキシ−7,9−ジオキソ−N−(2,4,6−トリフルオロベンジル)−2,3,4,5,7,9,13,13A−オクタヒドロ−2,5−メタノピリド[1’,2’:4,5]ピラジノ[2,1−b][1,3]オキサゼピン−10−カルボキサミドの結晶形
CA2950307C (en) Sodium (2r,5s,13ar)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepin-8-olate
JP2019524883A5 (enExample)
JP2013056886A5 (enExample)
JP2016537346A5 (enExample)
JP2017512186A5 (enExample)
JP2014507421A5 (enExample)
JP2014524442A5 (enExample)
JP2014503525A5 (enExample)
JP2015038149A5 (enExample)
JP2010500293A5 (enExample)
ME02612B (me) Tenofovir alafenamid hemifumarat
JP2010523522A5 (enExample)
JP2020517611A5 (enExample)
JP2017522276A5 (enExample)
JP2019504103A5 (enExample)
JP2018521969A5 (enExample)
CN116854745A (zh) 药物共晶组合物及其用途
JP2018521969A (ja) 医薬用共結晶及びその用途
JP2019516749A5 (enExample)
JP2018524320A5 (enExample)
JP2007522162A5 (enExample)
CN106687470A (zh) 结晶形式的索非布韦及其制备方法
TWI808069B (zh) [(1S)-1-[(2S,4R,5R)-5-(5-胺基-2-酮基-噻唑并[4,5-d]嘧啶-3-基)-4-羥基-四氫呋喃-2-基]丙基]乙酸酯之新穎固態形式